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Abstract Crizotinib is an anticancer drug used for the
treatment of non-small cell lung cancer. Evidences avail-
able suggest that there is a development of an acquired
resistance against crizotinib action due to the emergence of
several mutations in the ALK gene. It is therefore neces-
sary to develop potent anti-cancer drugs for the treatment
of crizotinib resistance non-small cell lung cancer types. In
the present study, a novel class of lead molecule was
identified using virtual screening, molecular docking and
molecular dynamic approach. The virtual screening anal-
ysis was done using PubChem database by employing
crizotinib as query and the data reduction was carried out
by using molecular docking techniques. The bioavailability
of the lead compounds was examined with the help of
Lipinski rule of five. The screened lead molecules were
analyzed for toxicity profiles, drug-likeness and other
physico-chemical properties of drugs by OSIRIS program.
Finally, molecular dynamics simulation was also per-
formed to validate the binding property of the lead com-
pound. Our analysis clearly indicates that CID 11562217, a
nitrile containing compound (pyrazole-substituted amino-
heteroaryl), could be the potential ALK inhibitor certainly
helpful to overcome the drug resistance in non-small cell
lung cancer.
Keywords Non-small cell lung cancer  Crizotinib 
Mutation  Virtual screening  Molecular docking 
Molecular dynamic simulation
Introduction
Lung cancer is the prominent cause of cancer deaths in the
world and a global issue to be addressed (Siegel et al.
2012). Lung cancer is broadly classified into two main
types based upon their histology, which are non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC).
The most common forms of NSCLC are adenocarcinoma
(ADC) and squamous cell carcinoma (SCC) (Skarda et al.
2008). Chromosomal rearrangements in the anaplastic
lymphoma kinase (ALK) gene that codes for anaplastic
lymphoma kinase has been identified as one of the causes
of NSCLC. There are two types of tyrosine kinase, receptor
and cytoplasmic tyrosine kinase. The ALK is a cytoplasmic
tyrosine kinase where crizotinib (a potential anticancer
drug used in the treatment of NSCLC) is bound. Chro-
mosomal rearrangements involving the ALK gene occur in
different malignant conditions, including anaplastic large
cell lymphoma (ALCL) and inflammatory myofibroblastic
tumor (IMT) (Chiarle et al. 2008). These rearrangements
lead to the expression of ALK fusion genes. ALK fusion
gene possesses different properties from the two genes that
it was originally derived from, can then code for the new
ALK fusion protein, which is abnormally and constitu-
tively activated. The new protein contains the tyrosine
kinase domain of ALK and the coiled coil domain of
EML4. The coiled coil domain of EML4 allows this pro-
tein to bind with other ALK fusion proteins and form
dimerised and activated fusion proteins (Katayama et al.
2012). The most prevalent ALK fusion oncogene in
NSCLC is the echinoderm microtubule-associated protein-
like 4 (EML4)–ALK fusion gene and is present in 4–5 %
of cases of NSCLC (Young et al. 2010). An inversion in
the chromosome 2 brings together the 50 end of the EML4
gene and the 30 end of the ALK gene resulting in the
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formation of the EML4-ALK fusion gene (Shaw and
Solomon 2011). The affected person tend to have typical
clinical features like early age of onset, little or absence of
any smoking history (Shaw et al. 2009). Some of the drugs
commonly used for the chemotherapeutic treatment of lung
cancer are Bevacizumab, Carboplatin, Cisplatin, Crizo-
tinib, Docetaxel, Erlotinib, Etoposide, Gemcitabine,
Irinotecan, Paclitaxel, Pemetrexed, and Vinorelbine. Tar-
geted drug therapy is used against NSCLC of which tyr-
osine kinase inhibitors are amongst the best method in
treatment methodology. In particular, crizotinib is one such
tyrosine kinase inhibitor which is the first drug to have
gained FDA approval for the treatment of NSCLC in 2011
(Ou, 2011). Although crizotinib has proved itself as an
efficient counter to ALK type NSCLC, acquired resistance
has made its beneficial effects temporary and has emerged
as a major roadblock for crizotinib. The literature evi-
dences available indicates that L1196M (the ‘‘gatekeeper’’
mutation) and G1269A are the two most commonly found
secondary mutations in the ALK kinase domain. In a few
cases, patient harbored with both mutation (Kim et al.
2013). Of note, the available evidence indicates that ALK
double mutation (L1196M, G1269A) is one of the main
causes for crizotinib resistance (Doebele et al. 2012;
Molina et al. 2008). The prevalence of ALK double
mutation (L1196M, G1269A) is also significantly higher
than other mutation. These situations urge the development
of new and more effective ALK inhibitors especially for
the treatment of drug resistance NSCLC. For years, com-
putational techniques in particular virtual screening (VS)
have proven to be of great use to make the drug develop-
ment process faster and less expensive. The available lit-
erature evidences also suggested that VS techniques proved
to be efficacious in making qualitative predictions that
discriminated active from inactive compounds (Oprea
2000; Chen 2008). Therefore, in the present investigation,
we have employed VS technique to address the crizotinib
resistance in NSCLC. We hope that this approach certainly
helpful for the experimental biologist to figure out the
potent candidates for NSCLC.
Materials and methods
Data set
The three-dimensional (3D) structure of native and mutant
(L1196M, G1269A) ALK structures were retrieved from
the crystal structures of the Brookhaven Protein Data Bank
(PDB) for the analysis (Berman et al. 2000). The corre-
sponding PDB codes were 2XP2 and 4ANS for the native
and mutant structures, respectively (Cui et al. 2011).
Crizotinib was used as the small molecule for our study.
The SMILES strings of the crizotinib and the lead mole-
cules were collected from PubChem (Feldman et al. 2006)
and submitted to CORINA for constructing the 3D struc-
ture of molecule (Gasteiger et al. 1990). The 3D structure
of target proteins (2XP2 and 4ANS) drug molecule and
lead compounds was energy-minimized using GROMACS
package 4.5.3 adopting the GROMOS43a1 force field
parameters before performing the computational analysis
(Hess et al. 2008; Spoel et al. 2005).
Virtual screening
Virtual Screening (Shoichet 2004) is an important tech-
nique in computer-assisted drug discovery for screening of
potential molecule from the database. This approach
becomes popular in the pharmaceutical research for lead
identification. Diminution of the massive virtual chemical
space of small organic molecules and to screen against a
specific target protein is the basic goal of the virtual
screening (Tondi et al. 1999). In the present study,
virtual screening technique performed with the help of
PubChem database by employing crizotinib as a query
(Bolton et al. 2008). It is worth stressing that PubChem
database holds over 27 million records of unique chemical
structures of compounds (CID) derived from nearly 70
million substance depositions (SID). The publicly available
PubChem database provides great opportunities for scien-
tists to perform VS process (Xie 2010). Several hits were
obtained from the PubChem database, which were further
analyzed using molecular docking studies.
ADME and toxicity
The bioavailability of the lead compounds was examined
with the help of Lipinski’s rule of five (Lipinski et al.
1997). The molecular properties such as logP (partition
coefficient), molecular weight (MW), or counts of hydro-
gen bond acceptors and donors in a molecule were utilized
in formulating ‘‘rule of five’’ (Ertl et al. 2000). The rule
states that most molecules with good membrane perme-
ability should have molecular weight B500, calculated
octanol–water partition coefficient, log P B 5, hydrogen
bond donors B5, acceptors B10 and van der Waals bumps
polar surface area (PSA)\120 A˚2 (Muegge 2003). In the
present study, all the molecular properties for all the lead
compounds were estimated by using Molinspiration pro-
gram (http://www.molinspiration.com/cgi-bin/properties)
(Buntrock 2002). Toxicity is the second important param-
eter need to be considered in the analysis of lead com-
pounds. Infact, toxicity will account the failure of majority
of the lead cases. In the present study, toxicity of the lead
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compound examined with the help of OSIRIS program
(http://www.organic-chemistry.org/prog/peo/). The pro-
gram was also helpful to evaluate the drug likeliness and
drug score of the lead compounds. Nearly 5300 distinct
substructure fragments created by 3300 traded drugs as
well as 15,000 commercially available chemicals yielding
a complete list of all available fragments with the associ-
ated drug likeliness. The drug score consolidates drug-
likeliness, cLogP, logS, molecular weight, and toxicity
risks. It is a total value which may be used to judge the
compound’s overall potential to qualify for a drug.
Molecular docking
The docking study is immensely important to understand the
bioactivity of the screened lead compounds. Initially,
SMILES strings were used for constructing three dimen-
sional structures of all the lead compounds. Subsequently,
docking algorithm was performed with the help of Patch
dock server (Schneidman et al. 2005). It is a molecular
docking algorithm based on geometry. The energy mini-
mized PDB coordinate file corresponds to the protein and the
ligandmolecule is the input parameters for the docking. This
algorithm has three major stages (1) molecular shape rep-
resentation (2) surface patch matching and (3) filtering and
scoring. The Patch Dock services were available at http://
bioinfo3d.cs.tau.ac.il/PatchDock/. The docked complexes
were ranked based on the geometric matching score with
target proteins. The geometric matching score of crizotinib
with target proteins (native and mutant structures) were used
as reference for filtering the lead compounds.
Molecular dynamics simulation
GROMACS Package 4.5.3 implemented with Gromos 43a1
force field was utilized to perform molecular dynamics (MD)
of docked complexes such as native-type ALK-crizotinib
complex, mutant-type ALK-crizotinib complex, native-type
ALK-CID11562217 complex and mutant-type ALK-
CID11562217 complex (Hess et al. 2008; Spoel et al. 2005).
The protein was solvated in cubic 0.9 nm with the help of
periodic boundary conditions and the SPC water model
(Meagher and Carlson 2005).This resulted in the addition of
22,269 and 23,506 water molecules to the native and mutant
complex structures, respectively. PRODRG server was used
to generate topology of the ligand (Schuttelkopf and Van
Aalten 2004). This server uses the GROMOS force field for
generating topology file and assigning atom types. Six sodium
(6 Na? ions) counter ions were added to neutralize the total
charge of the system and one thousand steps of steepest des-
cent energy minimization were carried out for the proteins.
After the energy minimization step, the system was equili-
brated at constant temperature and pressure. Using an atom-
based cutoff of 8 A˚, the non bonded list was generated.
Constrains bond lengths at their equilibrium values were
handled bySHAKEalgorithm and the long range electrostatic
interactions were handled by particle-mesh Ewald algorithm
(Darden et al. 1999;VanGunsteren andBerendsen 1977). The
total simulation time was set to 20,000 ps with integration
time step of 2 fs. Structural analysis was done at every
picosecond and trajectories were stored in traj.trr file. For
instance, root mean square deviation (RMSD) was analyzed
with the help of Gromacs utilities g_rms.
Results and discussion
Virtual screening and bioavailability analysis
The present study initiated by extracting structurally sim-
ilar compounds to crizotinib from the Pubchem database.
The crizotinib was used was used as a query molecule.
About 99 % similarity cutoff was maintained in the anal-
ysis. The results yield a total of 63 compounds. These
compounds were utilized for our further study. Molinspi-
ration program was used to predict the bioavailability of
crizotinib and the lead compounds. Initially, crizotinib
properties were calculated with the help of Molinspiration
program (Fig. 1) and used as a control for screening the
other lead compounds. The result is shown in Table 1. It is
clear from the table that 3 compound such as
CID: 11656144, CID: 11502981 and CID: 58659185
showed violations for the rule of five. The remaining 60
compounds have zero violations for the rule of five. This
brings to the conclusion that bioavailability of these 60
compounds was significantly better in our dataset.
It is bare that for passing oral bioavailability criteria,
number of rotatable bond should be \10 (Oprea 2000).
Therefore, we have made the further refinement of these
hits by restricting the number of rotatable bonds to 10. The
result is presented in Table 2. It is clear from the Table 2
that almost all the 60 compounds screened from the ADME
analysis possess reasonable number of rotatable bonds
(\10). This result indicates that these compounds may have
the potential to become a lead compound. However, toxi-
city is also one of the important issue could be addressed
for all the lead compounds before its selection.
Toxicity analysis
The primary objective behind the failure of the majority of
compounds in drug discovery process is the issues related
to pharmacokinetics and toxicity. In the present investi-
gation, these issues were addressed with the help of
OSIRIS property explorer program. The pharmacokinetic
property of a lead compound can be investigated by
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utilizing the parameters such as clogP and logS. The result
is shown in Table 3. clogP is an entrenched measure of the
compound’s hydrophilicity. The high log P values may
cause poor retention because of the compound’s low
hydrophilicity. It has been demonstrated that for com-
pounds to have a reasonable probability of being well
absorbed, their log P value must not be greater than 5.0. It
is clear from the table that log P values of all the 60
compounds found to be in the acceptable criteria.
Drug solubility normally affects the absorption and
distribution characteristics of a compound. Infact,
insufficient solubility of drug can lead to poor
absorption (Lipinski et al. 1997). Our evaluated log
S worth is a unit stripped logarithm (base 10) of a
compound’s dissolvability measured in mol/liter. There
are more than 80 % of the drugs available in the
market have an (expected) log S value greater than -4.
It is clear from the Table 3 that the solubility of the 60
lead compounds was found in the comparable zone
with that of standard drugs to fulfill the requirements
of solubility and this could be regarded as a candidate
drug for oral absorption.
Drug likeness
The drug likeliness is imperative parameter because drug
like molecules exhibit favorable absorption, distribution,
metabolism, excretion, toxicological (ADMET) parameters
(Tetko 2005). In this study, Osiris program was utilized to
calculate the drug-likeness of crizotinib and other virtually
screened compounds (Sander 2001). It is worth stressing
that the drug likeness value of 60 lead compounds was
found to be in acceptable criteria.
Drug score and toxicity
The information assessed in Table 3 shows that the 57 lead
compounds should be non-mutagenic and non-tumorigenic
impacts when run through the mutagenicity assessment
system comparable with standard drugs used. The com-
pounds such as CID: 11662380, CID: 58659189,
CID: 58659191, and CID: 58659192 failed to pass through
the Osiris program and showed mutagenic and tumorigenic
effects. We have also analyzed the overall drug score (DS)
for all the lead compounds and compared with that of
crizotinib. The score consolidates drug- likeness, miLogP,
logS, molecular weight, and toxicity risks. The DS score
could also be an important parameter to judge the com-
pound’s potential to meet all requirements to qualify for a
drug. The result is demonstrated in Table 3. The reported
lead compounds demonstrated moderate to good DS as
compared with standard drug crizotinib. In our dataset, 17
lead compounds showed similar drug score as that of
crizotinib. About five compounds such as CID: 11690598,
CID: 68563708, CID: 58659130, CID: 11676204 and
CID: 11575401 showed a drug score of 0.6 and above.
Therefore, further examination was carried out with 57
compounds.
Fig. 1 Molinspiration property
explorer showing molecular
properties of crizotinib
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Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration
S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume
1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175
2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175
3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175
4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175
5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175
6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175
7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175
8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175
9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175
10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175
11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175
12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175
13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175
14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175
15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175
16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175
17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175
18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175
19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564
20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175
21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175
22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977
23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107
24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589
25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441
26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441
27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441
28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441
29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118
30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92
31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118
32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507
33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989
34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735
35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571
36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571
37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218
38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758
39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571
40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53
41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204
42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147
43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92
44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92
45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671
46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175
47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374
48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175
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Molecular docking
Molecular docking program was employed to find out the
binding affinity of lead compounds with the target protein.
Docking analysis was performed twice to eliminate the
false positive. The docking results are shown in Table 4.
The docking score of native-type ALK-crizotinib complex
was found to be 5312 and for the mutant-type ALK-
crizotinib complex was found to be 4602. The lesser
docking score of mutant complex clearly indicates that
double mutation (L1196M and G1269A) significantly
affects the binding of crizotinib with the ALK structures. It
is believed that a potential lead compound is the one should
have higher docking scoring than the existing drug mole-
cule, crizotinib. Therefore, we have examined docking
score for all the 57 hits both with the native type and with
mutant type ALK systems. 16 hits showed higher docking
score only with mutant type ALK than native type ALK
and 17 more hits from our dataset showed similar dock
score to that of crizotinib. Most importantly, 10 hits from
our dataset showed higher score both in the native type as
well as with mutant type. For instance, CID 11562217
molecule showed the highest docking score among the 10
hits in our data set. The docking score of native-type ALK-
CID 11562217 complex was found to be 5662 and for the
mutant-type ALK-CID 11562217 complex was found to be
5908. This result indicates that CID 11562217 has a better
binding affinity not only with the native type but also with
mutant ALK as compared to the crizotinib.
It is also to be noted that the pharmacokinetic and
pharmacodynamic investigation of CID 11562217
indicated better results than the other lead compounds
explored in our study (Fig. 2). The two dimensional
structure of crizotinib was compared with CID 11562217 to
get the structural attributes and the result is demonstrated in
Fig. 3. It demonstrates that CID11562217 is a nitrile
enhanced crizotinib. It is worth stressing that nitrile com-
pounds with cyanide functional group could possess
potential anti-tumor effects (US Patent 20060128724). The
literature evidence also highlights that our lead molecule
has kinase inhibiting effects. Further, the cyano-containing
analogues were able to produce DNA–DNA cross-linking.
The reduced DNA cross-linking was paralleled by a similar
reduction in cytotoxicity indicating a relationship between
cross-linking and anti-tumor effect (Jesson et al. 1987).
Therefore, further validation of CID 11562217 compound
was done with the help of molecular dynamics simulation
study.
Molecular dynamics simulation
Molecular dynamics simulation study was carried out with
the help of GROMACS package 4.5.3 to explore the stability
of the complex structures. In particular, the parameter,
RMSD, was examined from the trajectory file and used for
analyzing the complex stability. RMSD investigation can
give a thought of how much the three-dimensional structure
has deviated over the time. The result is shown in Fig. 4.
Native type ALK-crizotinib complex structure acquired
*0.34 nm at 1000 ps during the simulations, while mutant
type ALK-crizotinib complex structure acquired*0.28 nm
of backbone RMSD at 1000 ps. On the other hand, native-
Table 1 continued
S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume
49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572
50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374
51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374
52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805
53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175
54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773
55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971
56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56
57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932
58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175
59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374
60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318
61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331
62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141
63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141
64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956
Bold indicates ADME screened compounds based on Lipinsiki rule of 5
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type ALK-CID11562217 structure acquired *0.18 nm of
backbone RMSD while mutant-type ALK-CID11562217
complex structure acquired*0.22 nm of backbone RMSD
at 1000 ps. Between a period of 2000–5000 ps, native type
ALK-crizotinib complex structure maintains a RMSD value
of*0.30 nmwhereas mutant type ALK-crizotinib complex
structure showed a deviation from*0.25 to*0.36 nm. In
the virtual complex, native-type ALK-CID11562217 struc-
ture showed a RMSD value between*0.18 and*0.20 nm
and mutant type ALK-CID11562217 complex structure
maintains a RMSD value of*0.24 nm. From the period of
5000–10,000 ps, native-type ALK-crizotinib complex
structure maintains a RMSD value of *0.34 nm while,
mutant type ALK-crizotinib complex has deviated from
*0.32 to *0.36 nm. On the contrary, native-type ALK-
CID11562217 complex structure maintains a RMSD value
of*0.25 nm while mutant type ALK-CID11562217 com-
plex structure maintains a RMSD value of *0.20 to
*0.24 nm. From the beginning of 11,000 ps to the end of
15,000 ps, mutant type ALK-crizotinib complex structure
showed higher deviation and attains a RMSD value of
*0.44 nm while native-type ALK-crizotinib complex
structure maintains a RMSD value of *0.23 nm. Mutant
type ALK-CID11562217 complex structure maintains a
RMSD value of *0.25 nm in this simulation period.
Between a period of 16,000–19,000 ps, native type ALK-
crizotinib complex structure maintains a RMSD value of
*0.35 nm whereas mutant type ALK-crizotinib complex
structure showed a deviation from*0.43 to*0.45 nm. For
instance, native-type ALK-CID11562217 structure showed
a RMSD value of *0.25 nm and mutant type ALK-
CID11562217 complex structure maintains a RMSD value
of*0.22 nm. At the end of 20,000 ps the mutant type ALK-
crizotinib complex structure attained RMSD of *0.40 nm
Table 2 Details of number of rotatable bonds
S. no Compound nrotb
1 Crizotinib 5
2 CID: 11597571 5
3 CID: 11626560 5
4 CID: 53234260 5
5 CID: 53234326 5
6 CID: 56671814 5
7 CID: 60197531 5
8 CID: 60197626 5
9 CID: 60198523 5
10 CID: 60198524 5
11 CID: 60198525 5
12 CID: 60199015 5
13 CID: 60199016 5
14 CID: 60199073 5
15 CID: 60199075 5
16 CID: 60199076 5
17 CID: 60199077 5
18 CID: 62705017 5
19 CID: 68625002 6
20 CID: 54613769 5
21 CID: 11662380 5
22 CID: 11626823 6
23 CID: 58659191 5
24 CID: 44560358 5
25 CID: 71239831 5
26 CID: 71239833 5
27 CID: 71240010 5
28 CID: 71240011 5
29 CID: 11496366 5
30 CID: 11562021 6
31 CID: 11626824 5
32 CID: 11598102 5
33 CID: 11641497 7
34 CID: 11690598 5
35 CID: 68563708 5
36 CID: 11562217 5
37 CID: 11612136 5
38 CID: 58659130 5
39 CID: 11625675 5
40 CID: 67084493 6
41 CID: 11676204 7
42 CID: 11684380 6
43 CID: 58659192 5
44 CID: 58659228 5
45 CID: 11503318 6
46 CID: 11510387 5
47 CID: 11568619 6
48 CID: 11575401 5
Table 2 continued
S. no Compound nrotb
49 CID: 11647760 5
50 CID: 58659136 5
51 CID: 58659189 5
52 CID: 72986690 6
53 CID: 11676140 5
54 CID: 58659141 6
55 CID: 11705849 5
56 CID: 11719356 5
57 CID: 11647759 6
58 CID: 21110753 7
59 CID: 21110757 4
60 CID: 73386634 4
61 CID: 11647795 5
Number of rotatable bonds\10
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Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer
S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score
1 Crizotinib No No No 3.54 -5.26 3.12 0.52
2 CID: 11597571 No No No 3.54 -5.26 3.12 0.52
3 CID: 11626560 No No No 3.54 -5.26 3.12 0.52
4 CID: 53234260 No No No 3.54 -5.26 3.12 0.52
5 CID: 53234326 No No No 3.54 -5.26 3.12 0.52
6 CID: 56671814 No No No 3.54 -5.26 3.12 0.52
7 CID: 60197531 No No No 3.54 -5.26 3.12 0.52
8 CID: 60197626 No No No 3.54 -5.26 3.12 0.52
9 CID: 60198523 No No No 3.54 -5.26 3.12 0.52
10 CID: 60198524 No No No 3.54 -5.26 3.12 0.52
11 CID: 60198525 No No No 3.54 -5.26 3.12 0.52
12 CID: 60199015 No No No 3.54 -5.26 3.12 0.52
13 CID: 60199016 No No No 3.54 -5.26 3.12 0.52
14 CID: 60199073 No No No 3.54 -5.26 3.12 0.52
15 CID: 60199075 No No No 3.54 -5.26 3.12 0.52
16 CID: 60199076 No No No 3.54 -5.26 3.12 0.52
17 CID: 60199077 No No No 3.54 -5.26 3.12 0.52
18 CID: 62705017 No No No 3.54 -5.26 3.12 0.52
19 CID: 68625002 No No No 3.78 -5.69 3.68 0.46
20 CID: 54613769 No No No 3.54 -5.26 3.22 0.53
21 CID: 11662380 No No Yes 3.54 -5.26 2.78 0.42
22 CID: 11626823 No No No 3.29 -5.78 3.45 0.48
23 CID: 58659191 No Yes No 3.64 -5.58 3.17 0.29
24 CID: 44560358 No No No 3.25 -5.19 2.42 0.54
25 CID: 71239831 No No No 4.19 -5.96 1.79 0.38
26 CID: 71239833 No No No 4.19 -5.96 1.45 0.37
27 CID: 71240010 No No No 4.19 -5.96 1.79 0.38
28 CID: 71240011 No No No 4.19 -5.96 1.79 0.38
29 CID: 11496366 No No No 3.79 -4.90 7.62 0.54
30 CID: 11562021 No No No 4.2 -5.22 7.51 0.48
31 CID: 11626824 No No No 3.79 -4.90 7.62 0.54
32 CID: 11598102 No No No 3.89 -6.11 2.11 0.41
33 CID: 11641497 No No No 2.38 -4.53 4.34 0.49
34 CID: 11690598 No No No 3.03 -4.84 3.12 0.6
35 CID: 68563708 No No No 3.03 -4.84 3.12 0.6
36 CID: 11562217 No No No 3.44 -5.35 2.82 0.29
37 CID: 11612136 No No No 3.68 -5.4 -0.93 0.33
38 CID: 58659130 No No No 3.03 -4.84 3.22 0.60
39 CID: 11625675 No No No 3.75 -5.39 2.56 0.53
40 CID: 67084493 No No No 4.04 -6.15 1.21 0.37
41 CID: 11676204 No No No 2.28 -4.96 3.76 0.62
42 CID: 11684380 No No No 3.55 -5.42 7.62 0.54
43 CID: 58659192 No Yes No 4 -6.42 2.17 0.22
44 CID: 59599446 No No No 2.47 -5.33 4.07 0.53
45 CID: 11503318 No No No 3.01 -5.73 0.63 0.42
46 CID: 11510387 No No No 3.30 -6.39 3.37 0.47
47 CID: 11568619 No No No 3.01 -5.73 0.63 0.42
48 CID: 11575401 No No No 2.85 -4.72 3.34 0.63
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Table 3 continued
S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score
49 CID: 11647760 No No No 3.20 -4.99 3.81 0.58
50 CID: 58659136 No No No 3.20 -4.99 3.81 0.48
51 CID: 58659189 Yes No No 3.78 -5.29 4.46 0.31
52 CID: 72986690 No No No 3.01 -5.73 0.63 0.42
53 CID: 11676140 No No No 4.16 -5.75 1.66 0.44
54 CID: 58659141 No No No 3.44 -5.91 -0.32 0.33
55 CID: 11705849 No No No 4.15 -5.74 2.96 0.42
56 CID: 11719356 No No No 3.63 -4.96 2.31 0.53
57 CID: 11647759 No No No 2.61 -5.24 3.45 0.57
58 CID: 21110753 No No No 2.52 -4.67 3.67 0.59
59 CID: 21110757 No No No 3.00 -5.47 2.35 0.56
60 CID: 73386634 No No No 3.00 -5.47 2.35 0.56
61 CID: 11647795 No No No 3.34 -5.13 0.85 0.48
Table 4 Docking score of the crizotinib and lead compounds
obtained from PubChem database against the target structure
S. no Compound ID Score
2XP2 4ANS
1 Crizotinib 5312 5226
2 CID: 11597571 5312 5226
3 CID: 11626560 5312 5226
4 CID: 53234260 5312 5226
5 CID: 53234326 5312 5226
6 CID: 56671814 5312 5226
7 CID: 60197531 5312 5226
8 CID: 60197626 5312 5226
9 CID: 60198523 5312 5226
10 CID: 60198524 5312 5226
11 CID: 60198525 5312 5226
12 CID: 60199015 5312 5226
13 CID: 60199016 5312 5226
14 CID: 60199073 5312 5226
15 CID: 60199075 5312 5226
16 CID: 60199076 5312 5226
17 CID: 60199077 5312 5226
18 CID: 62705017 5312 5226
19 CID: 68625002 5200 5342
20 CID: 54613769 5298 5308
21 CID: 11626823 5048 5226
22 CID: 44560358 5012 5386
23 CID: 71239831 5440 5776
24 CID: 71239833 5440 5776
25 CID: 71240010 5426 5504
26 CID: 71240011 5426 5504
27 CID: 11496366 5412 5420
28 CID: 11562021 5510 5492
29 CID: 11626824 5412 5420
Table 4 continued
S. no Compound ID Score
2XP2 4ANS
30 CID: 11598102 5292 5294
31 CID: 11641497 5450 5138
32 CID: 11690598 4906 5138
33 CID: 68563708 4906 5138
34 CID: 11562217 5662 5908
35 CID: 11612136 5144 5032
36 CID: 58659130 5108 5294
37 CID: 11625675 4746 5052
38 CID: 67084493 4950 5334
39 CID: 11676204 4964 4962
40 CID: 11684380 4964 5424
41 CID: 59599446 5434 5704
42 CID: 11503318 5110 5138
43 CID: 11510387 5124 5372
44 CID: 11568619 5110 5138
45 CID: 11575401 4886 4826
46 CID: 11647760 5124 5372
47 CID: 58659136 5124 5372
48 CID: 72986690 5110 5138
49 CID: 11676140 4906 5484
50 CID: 58659141 5118 5278
51 CID: 11705849 5186 5370
52 CID: 11719356 5040 5238
53 CID: 11647759 5026 5118
54 CID: 21110753 5390 5526
55 CID: 21110757 4408 4604
56 CID: 73386634 4408 4604
57 CID: 11647795 5268 5212
Bold indicates the lead compounds showed higher binding score than
crizotinib
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and native type ALK-crizotinib complex structure attained
RMSDof*0.35 nm.This clearly indicates thatALKdouble
mutation disturb the structural stability and also its function.
It is worth stressing that native and mutant type ALK-CID
11562217 able to maintain a RMSD of*0.24 nm. Overall,
significant difference in RMSD value observed between the
crizotinib and CID 11562217 complex system. The lesser
RMSD value of CID 11562217 complex demonstrates the
stable binding of CID 11562217 with both native andmutant
type ALK structures.
Conclusion
In the present investigation, we have addressed the crizo-
tinib resistance in NSCLC with the help of virtual
screening approach. CID 11562217 was discovered to be
Fig. 2 Osiris property explorer
showing drug-likeliness
properties of CID11562217
Fig. 3 Structure comparison
between (a) crizotinib and
(b) CID11562217
Fig. 4 Root mean square deviations correspond to native-type ALK-
crizotinib complex (black), mutant-type ALK-crizotinib complex
(red), native-type ALK-CID11562217 complex (green) and mutant-
type ALK-CID11562217 complex (blue) along the MD simulation at
300 K
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more drug like as it productively passed through the
parameters of pharmacokinetics and toxicity. Docking
study demonstrated that CID 11562217 has the highest
binding affinity not only with native type ALK but also
with the mutant type ALK system among the lead com-
pounds screened from the Pubchem database. RMSD data
obtained from molecular dynamic simulation revealed
structural stability of the ALK-CID11562217 complex
structure. It is worth stressing that our results correlate well
with available experimental evidences. Of note, the avail-
able data suggests that pyrazole-substituted amino-
heteroaryl compounds have potential anti-tumor effects.
We hope that the findings reported here might give helpful
signs to design powerful drugs against drug resistant lung
cancer types.
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